CSL Limited announces that its subsidiary, CSL Seqirus, has entered into a collaboration and license agreement with Arcturus Therapeutics Holdings Inc ("Arcturus Therapeutics") to...
Ascletis Pharma Inc. announces that the Investigational New Drug (IND) application of ASC11, an oral inhibitor drug candidate targeting 3-chymotrypsin like protease (3CLpro) for...
Avirmax CMC Inc., a global leader in recombinant adeno associate virus vector (rAAV) innovation and manufacturing process development, using a recombinant baculovirus Sf9 (rBV-Sf9-AAV)...
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group ("Menarini"), a privately-held, leading international pharmaceutical company, announced that...
